Adventris Pharmaceuticals
Adventris makes cancer vaccines
Adventris makes cancer vaccines. By teaching our body’s immune system to recognize and kill the drivers of cancer, we can eliminate the majority of all cancer deaths. A little more detail to understand our scientific approach: A normal cell turns into cancer when it develops a mutation that makes it grow aggressively. Surprisingly, a small number of these mutations account for the vast majority of cancer deaths. The immune system usually doesn’t recognize these mutations, but our technology platform enables us to train the immune system to recognize and attack these cancers. Our first product is a vaccine for the treatment of lung cancer that targets the KRAS mutation, the most common mutation in cancer, accounting for about 30% of all cancer deaths. In the long run, we envision a world where every adult receives our vaccines annually – preventing the majority of cancer deaths. Our team includes some of the leading cancer vaccine experts in the world including: our Chief Scientific Officer, Dr. Liz Jaffee (Chair of President Biden’s Cancer Advisory Panel) and our Chief Medical Officer, Dr. Mark Yarchoan (principal investigator of multiple cancer vaccine clinical trials). Our team is led by our Chief Executive Officer, Jen Herbach, who has more than a decade of biotech industry experience including with Amunix (the second largest oncology pre-clinical stage acquisition). If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventrispharma.com
Active Founders
Jen Herbach
Jen Herbach is the CEO of Adventris Pharmaceuticals. She has more than a decade of biotech industry experience bringing novel oncology drugs to market, across companies including Onyx/Amgen, InterMune/Genentech, Exelixis, and Amunix. She holds an MBA from Harvard Business School and a Masters from the University of Cambridge.
William Collis
William Collis is a serial entrepreneur with multiple exits, most recently the data platform Genji. His research has been published in Harvard Business review and featured as a TED talk with over 1.5M views. He holds an MBA from Harvard Business School where he was named a Baker Scholar. He is lifelong friends with his co-founders Jen Herbach and Mark Yarchoan, since meeting as roommates at Amherst College.
Mark Yarchoan
Mark Yarchoan, M.D, is an Associate Professor of Medical Oncology at Johns Hopkins. Dr. Yarchoan runs an NCI-funded laboratory focused on developing novel immunotherapies, with a focus on cancer vaccines. He has led multiple international clinical trials of immunotherapy agents including neoantigen-targeted cancer vaccines. Dr. Yarchoan has received multiple honors, including the ASCO Young Investigator Award and the ASCO Career Development Award.
Company Launches
ABOUT ADVENTRIS
Adventris makes cancer vaccines. By teaching our body’s immune system to recognize and kill the mutations that cause cancer, we can eliminate the majority of all cancer deaths.
OUR SCIENCE
A normal cell turns into cancer when it develops a mutation that makes it grow aggressively. Surprisingly, a small number of these mutations account for the vast majority of cancer deaths. The immune system usually doesn’t recognize these mutations, but our technology platform enables us to train the immune system to recognize and attack these cancers. Our first product is a vaccine for the treatment of lung cancer that targets the KRAS mutation, the most common mutation in cancer, accounting for about 25-30% of all cancer deaths. In the long run, we envision a world where every adult receives our vaccines annually – preventing the majority of cancer deaths.
OUR TEAM
Our team includes some of the leading cancer vaccine experts in the world including: our Chief Scientific Officer, Dr. Liz Jaffee (Chair of President Biden’s Cancer Advisory Panel) and our Chief Medical Officer, Dr. Mark Yarchoan (principal investigator of multiple international cancer vaccine clinical trials). Our team is led by our Chief Executive Officer, Jen Herbach, who has more than a decade of biotech industry experience including with Amunix (the second largest oncology pre-clinical stage acquisition).
INTERESTED IN LEARNING MORE
If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventrispharma.com